Published in Drug Saf on January 01, 2005
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol (2010) 1.22
Natural product-derived drugs for the treatment of inflammatory bowel diseases. Intest Res (2014) 0.78
Nutrition of the critically ill — a 21st-century perspective. Nutrients (2013) 0.78
Nutrition of the critically ill - emphasis on liver and pancreas. Hepatobiliary Surg Nutr (2012) 0.77
Evaluation of apoptosis in immunotoxicity testing. Methods Mol Biol (2010) 0.76
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. Int J Nanomedicine (2016) 0.75